Predict your next investment

Corporate Venture

See what CB Insights has to offer

Investments

91

Portfolio Exits

23

Funds

1

Partners & Customers

4

About Takeda Ventures

Takeda Ventures, (TVI), is the corporate venture arm of Takeda Pharmaceutical Company (TPC) a world-class pharmaceutical company and the largest in Japan. TVI now assumes the role of Takedas former venture investment group, Takeda Research Investment, and remains a wholly owned subsidiary of Takeda America Holdings.The new group continues to seek strategic opportunities to complement and extend internal discovery capabilities, but will additionally explore potentially new business avenues for Takeda through external strategic venture activities. The firm's aim is to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.

Takeda Ventures Headquarter Location

435 Tasso Street, Suite 300

Palo Alto, California, 94301,

United States

650-328-2922

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Takeda Ventures News

Code Biotherapeutics Raises $75M in Series A

Jun 9, 2022

Back to HomeHATFIELD, PA, Code Biotherapeutics, a biotechnology company, announced its Series A financing of $75 million led by Northpond Ventures.Code Biotherapeutics, a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announced its upsized and oversubscribed Series A financing of $75 million to advance programs to treat and cure rare and prevalent genetic diseases.Northpond Ventures led the financing round with participation from Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, the JDRF T1D Fund, UPMC Enterprises, and Takeda Ventures. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.

Takeda Ventures Investments

91 Investments

Takeda Ventures has made 91 investments. Their latest investment was in Code Biotherapeutics as part of their Series A on June 6, 2022.

CBI Logo

Takeda Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/7/2022

Series A

Code Biotherapeutics

$75M

No

7

4/14/2022

Series B

Be Biopharma

$130M

No

2

2/7/2022

Series C

Koneksa

$45M

Yes

4

12/17/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/7/2022

4/14/2022

2/7/2022

12/17/2021

12/2/2021

Round

Series A

Series B

Series C

Series A

Seed VC

Company

Code Biotherapeutics

Be Biopharma

Koneksa

Subscribe to see more

Subscribe to see more

Amount

$75M

$130M

$45M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

2

4

10

10

Takeda Ventures Portfolio Exits

23 Portfolio Exits

Takeda Ventures has 23 portfolio exits. Their latest portfolio exit was Bioniz Therapeutics on February 16, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/16/2022

Acquired

$99M

2

10/22/2021

IPO

$99M

Public

10

12/15/2020

Acquired

$99M

1

11/5/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/12/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/16/2022

10/22/2021

12/15/2020

11/5/2020

6/12/2020

Exit

Acquired

IPO

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

10

1

10

10

Takeda Ventures Fund History

1 Fund History

Takeda Ventures has 1 fund, including TRI Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

TRI Fund

UNKNOWN

Open

1

Closing Date

Fund

TRI Fund

Fund Type

UNKNOWN

Status

Open

Amount

Sources

1

Takeda Ventures Partners & Customers

4 Partners and customers

Takeda Ventures has 4 strategic partners and customers. Takeda Ventures recently partnered with Crescendo Biologics on July 7, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

7/23/2019

Licensor

United Kingdom

Crescendo Biologics Second Oncologytargeted Humabody Licensed by Takeda

This is the second license option that Takeda Ventures has exercised under the agreement with Crescendo Biologics and relates to the continued progression of an immuno-oncology programme .

1

3/28/2019

Licensee

United States

Subscribe to see more

Subscribe to see more

10

3/2/2017

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

4/11/2011

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

7/23/2019

3/28/2019

3/2/2017

4/11/2011

Type

Licensor

Licensee

Partner

Partner

Business Partner

Country

United Kingdom

United States

United Kingdom

United Kingdom

News Snippet

Crescendo Biologics Second Oncologytargeted Humabody Licensed by Takeda

This is the second license option that Takeda Ventures has exercised under the agreement with Crescendo Biologics and relates to the continued progression of an immuno-oncology programme .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Takeda Ventures Team

8 Team Members

Takeda Ventures has 8 team members, including current Chief Executive Officer, President, Graeme R Matin.

Name

Work History

Title

Status

Graeme R Matin

Chief Executive Officer, President

Current

Sacha Mann

Novateur Ventures, Zoic Capital, adMare BioInnovations, Biosys, Inventages Venture Capital, and Archangels Investors

Senior Partner

Current

Miles Gerson

Senior Director

Current

Graeme R. Martin

Roche, and GSK

Chief Executive Officer, President

Former

Koichi Kato

Senior Vice President

Former

Name

Graeme R Matin

Sacha Mann

Miles Gerson

Graeme R. Martin

Koichi Kato

Work History

Novateur Ventures, Zoic Capital, adMare BioInnovations, Biosys, Inventages Venture Capital, and Archangels Investors

Roche, and GSK

Title

Chief Executive Officer, President

Senior Partner

Senior Director

Chief Executive Officer, President

Senior Vice President

Status

Current

Current

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.